<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">Dyslipidemia</z:e> is common in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="35664">Statins</z:chebi> are used as the first choice in treatment of diabetic <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidemia</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain><z:chebi fb="0" ids="39548">Atorvastatin</z:chebi> represents a first-line treatment option, alongside other <z:chebi fb="10" ids="29191">hydroxyl</z:chebi> methylglutaryl <z:chebi fb="3" ids="15346">coenzyme A</z:chebi> reductase inhibitors </plain></SENT>
<SENT sid="3" pm="."><plain>Repaglinide is a short-acting, oral, insulin secretagogue that is used in the treatment of type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>Both the category of drugs undergo extensive metabolism with <z:chebi fb="0" ids="4056">cytochrome</z:chebi> enzyme system </plain></SENT>
<SENT sid="5" pm="."><plain>This may lead to drug-drug interaction problems with altered repaglinide activity which is cautious </plain></SENT>
<SENT sid="6" pm="."><plain>Repaglinide/<z:chebi fb="0" ids="39548">atorvastatin</z:chebi>/<z:chebi fb="0" ids="39548">atorvastatin</z:chebi> + repaglinide were administered orally to <z:mpath ids='MPATH_458'>normal</z:mpath>, diabetic rats, and to <z:mpath ids='MPATH_458'>normal</z:mpath> rabbits </plain></SENT>
<SENT sid="7" pm="."><plain>Blood samples were collected at different time intervals and were analyzed for blood <z:chebi fb="105" ids="17234">glucose</z:chebi> by GOD-POD method using commercial <z:chebi fb="105" ids="17234">glucose</z:chebi> kits and repaglinide estimation in plasma by HPLC method </plain></SENT>
<SENT sid="8" pm="."><plain><z:mp ids='MP_0002055'>Diabetes</z:mp> was induced by alloxan 100 mg/kg body weight administered by I.P route </plain></SENT>
<SENT sid="9" pm="."><plain>In the presence of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi>, repaglinide activity was increased and maintained for longer period in diabetic rats compared with repaglinide matching control </plain></SENT>
<SENT sid="10" pm="."><plain>The present study concludes co-administration of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> was found to improve repaglinide responses significantly in diabetic rats and improved <z:chebi fb="105" ids="17234">glucose</z:chebi> metabolism of <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> played an important role and increased repaglinide levels by competitive <z:chebi fb="0" ids="38559">CYP</z:chebi> 3A4 <z:e sem="disease" ids="C0877008" disease_type="Disease or Syndrome" abbrv="">enzyme inhibition</z:e> by <z:chebi fb="0" ids="39548">atorvastatin</z:chebi> could be added advantage for anti hyperglycemic activity </plain></SENT>
</text></document>